首页> 外文期刊>Cancer immunology, immunotherapy : >Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma
【24h】

Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma

机译:从胃腺癌患者肿瘤组织中分离的肿瘤抗原肽特异性T细胞的表征

获取原文
获取原文并翻译 | 示例
           

摘要

Gastric cancer is a significant cause of morbidity and mortality worldwide. Surgical resection remains the primary curative treatment for gastric adenocarcinoma, but the poor (15-35%) survival rate at 5 years has prompted many studies for new therapeutic strategies, such as specific immunotherapy. The aim of this study was to analyze the functional properties of the T cell response to different antigen peptides related to gastric cancer in patients with gastric adenocarcinoma. To this purpose, we have cloned and characterized tumor-infiltrating T cells (TILs) isolated from the neoplastic gastric tissue samples. A T cell response specific to different peptides of gastric cancer antigens tested was documented in 17 out of 20 patients, selected for their HLA-A02 and/or -A24 alleles. Most of the cancer peptide-specific TILs expressed a Th1/Tc1 profile and cytotoxic activity against target cells. The effector functions of cancer peptide-specific T cells obtained from the peripheral blood of the same patients were also studied. The majority of peripheral blood peptide-specific T cells also expressed the Th1/Tc1 functional profile. In conclusion, in most of the patients with gastric adenocarcinoma, a specific type-1 T cell response to gastric cancer antigens was detectable and would have the potential of hamper tumor cell growth. However, in order to get tumor cell killing in vivo, the activity and the number of cancer peptide-specific Th1/Tc1 cells probably need to be enhanced by vaccination with the appropriate cancer antigenic peptides or by injection of the autologus tumor peptide-specific T cells expanded in vitro.
机译:胃癌是全世界发病率和死亡率的重要原因。手术切除仍是胃腺癌的主要治疗方法,但是5年生存率低(15-35%)促使许多研究针对新的治疗策略进行了研究,例如特异性免疫疗法。这项研究的目的是分析胃腺癌患者对与胃癌相关的不同抗原肽的T细胞应答的功能特性。为了这个目的,我们已经克隆并表征了从赘生性胃组织样品中分离的肿瘤浸润性T细胞(TIL)。在针对其HLA-A02和/或-A24等位基因选择的20例患者中,有17例记录了对所测试的胃癌抗原不同肽具有特异性的T细胞应答。大多数癌症肽特异性TILs表达Th1 / Tc1图谱和针对靶细胞的细胞毒活性。还研究了从相同患者外周血中获得的癌肽特异性T细胞的效应子功能。大多数外周血肽特异性T细胞也表达Th1 / Tc1功能。总之,在大多数胃腺癌患者中,可以检测到对胃癌抗原的特异性1型T细胞应答,并且有可能阻碍肿瘤细胞的生长。但是,为了在体内杀死肿瘤细胞,可能需要通过接种适当的癌症抗原肽或注射自体肿瘤肽特异性T来增强癌症肽特异性Th1 / Tc1细胞的活性和数量。细胞在体外扩增。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号